We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
No fiscal-year history available for this company yet.
No P/E, the company is not profitable on a trailing basis.
GenFleet Therapeutics (Shanghai) Inc., a biopharmaceutical company, develops treatment options in the fields of oncology, autoimmune, and inflammatory diseases in the United States. The company develops GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C in a Phase III trial for the treatment of pancreatic cancer, as well as in Phase II trials for the treatment of non-small cell lung cancer (NSCLC) and BTC, and in a Phase I trial for the treatment of solid tumors; GFH925, a small molecule selective inhibitor of KRAS G12C in a Phase II trial for the treatment of advanced NSCLC; and GFH009, a highly selective cyclin-dependent kinase (CDK) 9 inhibitor in a Phase II trial for the treatment of AML. It is also developing GFH276, a pan-RAS inhibitor in a Phase I trial for the treatment of solid tumors; GFS202A, a bispecific antibody in a Phase I trial for the treatment of cachexia; GFH312, a receptor-interacting serine/threonine-protein kinase (RIPK) 1 inhibitor in a Phase I clinical trial for the treatment of PAD with IC and PBC; GFS784, a pan-RAS antibody drug conjugate (ADC) candidate with an IND application for the treatment of solid tumors; and GFH946, an oral PROTAC product candidate with an IND application for the treatment of type 2 inflammation. In addition, the company offers technical services. It has collaboration agreements with Merck Healthcare KGaA for trials of combinational regimens, including cetuximab; Verastem, Inc. to develop and commercialize GFH375; and SELLAS Life Sciences Group, Inc. to develop, manufacture, and commercialize GFH009. GenFleet Therapeutics (Shanghai) Inc. was incorporated in 2017 and is headquartered in Shanghai, China.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 2595.HK and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
